Theravance Biopharma

Theravance Biopharma Inc. is a biopharmaceutical company focused on developing and commercializing medicines for respiratory disease and selected specialized conditions. Its commercial portfolio is centered on YUPELRI, an inhaled therapy used in chronic obstructive pulmonary disease (COPD), supported by a broader respiratory franchise that addresses patient needs in outpatient and clinical care settings. The company also pursues medicines for rare and complex disorders, including ampreloxetine, an investigational therapy studied for symptomatic neurogenic orthostatic hypotension associated with multiple system atrophy. Theravance Biopharma Inc. works across research, clinical development, and product commercialization, giving it a role in advancing treatments from late-stage development to market access. Based in South San Francisco, California, the company operates as a focused healthcare business serving physicians, patients, and healthcare systems with therapies designed for chronic management and specialty care.